Search

Displaying results 6311 - 6320 of 7062 in total
  1. Drug

    Hexocyclium

    go.drugbank.com/drugs/DB06787
    Approved

    Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea.

  2. Drug

    Sulconazole

    go.drugbank.com/drugs/DB06820
    Approved

    Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution.

  3. Drug

    Triptorelin

    go.drugbank.com/drugs/DB06825
    ApprovedInvestigationalVet approved

    Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH).

    Synonyms: (D-Trp6)-GnRH, pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Products: Pamorelin LA 22,5 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension, Pamorelin LA 3,75 mg Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension
  4. Drug

    Viomycin

    go.drugbank.com/drugs/DB06827
    Approved

    Viomycin is a tuberactinomycin antibiotic that was used to treat Mycobacterium tuberculosis until it was replaced by the less toxic capreomycin.

    Synonyms: Vinacetin A
  5. Drug

    Dimetindene

    go.drugbank.com/drugs/DB08801
    ApprovedInvestigational

    Dimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.

  6. Drug

    Roxatidine acetate

    go.drugbank.com/drugs/DB08806
    Investigational

    Roxatidine acetate is a specific and competitive H2 receptor antagonist. It is currently approved in South Africa under the tradename Roxit.

  7. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. … [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  8. Drug

    Iodamide

    go.drugbank.com/drugs/DB08948
    ApprovedWithdrawn

    Iodamide is a contrast medium molecule that is no longer marketed in the United States.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Etilefrine

    go.drugbank.com/drugs/DB08985
    ApprovedWithdrawn

    It has been used as a vasoconstrictor agent.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.